X4 Pharmaceuticals Inc

NASDAQCM:XFOR

Stati Uniti / Sanità / Biotecnologia

Panoramica

Notizie

Cronol. dati finanziari 5 anni

Prezzo azione

0,25 USD


Key Metrics	Latest
Total Revenue	2,557 M
Adjusted EBITDA	-140,7 M
EBITDA Margin	-5.502,7%
Net Profit Margin	-4.503,3%
Total Assets	146,4 M
Total Debt	78,086 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	3.00	0.00	0.00	0.00	2.56	2.56	0.00	2.56
% Growth		(1.00)	NA	NA	NA			NA

Adjusted EBITDA	(59.52)	(74.85)	(87.57)	(107.10)	(140.70)	(140.70)	(107.10)	(140.70)
% Margin	(19.84)	NA	NA	NA	(55.03)	(55.03)	NA	(55.03)

Adjusted EBIT	(59.87)	(75.35)	(88.08)	(107.52)	(141.40)	(141.40)	(107.52)	(141.40)
% Margin	(19.96)	NA	NA	NA	(55.30)	(55.30)	NA	(55.30)

Adjusted Net Income	(62.01)	(81.48)	(94.24)	(101.17)	(115.15)	(115.15)	(101.17)	(115.15)
% Margin	(20.67)	NA	NA	NA	(45.03)	(45.03)	NA	(45.03)

Adjusted Basic EPS	(3.09)	(3.16)	(1.48)	(0.57)	(0.57)	(0.57)	(0.57)	(0.57)

Calcoli supportati

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Press Release
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	3	0	0	0	3	3	0	3
% Growth	NA	-100.0%	NA	NA	NA			NA

Cost of Revenue	0	0	0	0	(1)	(1)	0	(1)
Gross Profit	3	0	0	0	2	2	0	2
% Revenue	100.0%	NA	NA	NA	68.8%	68.8%	NA	68.8%

Research and Development	(42)	(51)	(61)	(72)	(82)	(82)	(72)	(82)
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(21)	(25)	(27)	(36)	(62)	(62)	(36)	(62)
Other Inc / (Exp)	0	(10)	(2)	8	104	104	8	104
Total Operating Exp	(63)	(85)	(90)	(100)	(39)	(39)	(100)	(39)

Operating Income	(60)	(85)	(90)	(100)	(37)	(37)	(100)	(37)
% Revenue	-1985.6%	NA	NA	NA	-1452.5%	-1452.5%	NA	-1452.5%

Interest Expense	(2)	(4)	(4)	(1)	0	0	(1)	0
Pre-tax Income	(62)	(89)	(94)	(101)	(37)	(37)	(101)	(37)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Net Income to Company	(62)	(89)	(94)	(101)	(37)	(37)	(101)	(37)
% Margin	-2071.0%	NA	NA	NA	-1464.6%	-1464.6%	NA	-1464.6%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	(62)	(89)	(94)	(101)	(37)	(37)	(101)	(37)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	(14)	(3)	0	0	0	0	0

Net Income to Common	(62)	(103)	(96)	(101)	(37)	(37)	(101)	(37)
% Margin	-2071.0%	NA	NA	NA	-1464.6%	-1464.6%	NA	-1464.6%

As Reported
Basic EPS (Continuing Ops)	(3.09)	(3.99)	(1.52)	(0.57)	(0.19)	(0.19)	(0.57)	(0.19)
Diluted EPS (Continuing Ops)	(3.09)	(3.99)	(1.52)	(0.57)	(0.19)	(0.19)	(0.57)	(0.19)

WA Basic Shares Out.	20.08	25.75	63.53	177.81	201.06	201.06	177.81	201.06
WA Diluted Shares Out.	20.08	25.75	63.53	177.81	201.06	201.06	177.81	201.06

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(62)	(89)	(94)	(101)	(37)	(37)	(101)	(37)
Addback: Net Interest Expense	2	4	4	1	0	0	1	0
Addback: Other Non Operating Expenses, Total	(0)	(0)	2	(8)	1	1	(8)	1
Addback: Depreciation & Amortization	0	0	1	0	1	1	0	1
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	10	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	(1)	0	(105)	(105)	0	(105)
Addback: Asset Writedown	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	0	0	0
Adjusted EBITDA	(60)	(75)	(88)	(107)	(141)	(141)	(107)	(141)
% Margin	-1984.1%	NA	NA	NA	-5502.7%	-5502.7%	NA	-5502.7%

Adjusted EBIT	(60)	(75)	(88)	(108)	(141)	(141)	(108)	(141)
% Margin	-1995.8%	NA	NA	NA	-5530.0%	-5530.0%	NA	-5530.0%

Adjusted Net Income Reconciliation
Net Income to Company	(62)	(89)	(94)	(101)	(37)	(37)	(101)	(37)
Addback: Unusual Items	0	10	(1)	0	(105)	(105)	0	(105)
Less: Tax Benefit of Unusual Items (26%)	(0)	(3)	0	0	27	27	0	27
Adjusted Net Income	(62)	(81)	(94)	(101)	(115)	(115)	(101)	(115)
% Margin	-2067.0%	NA	NA	NA	-4503.3%	-4503.3%	NA	-4503.3%

Errore di caricamento

X4 Pharmaceuticals Inc

NASDAQCM:XFOR

Stati Uniti / Sanità / Biotecnologia

Cronol. dati finanziari 5 anni